Home » Authors » Mark McCarty

Articles by Mark McCarty

San Diego chosen as first site for CMS lab bidding project

Oct. 18, 2007

By Mark McCarty

CMS set to roll out P4P demo project for home healthcare

Oct. 17, 2007

By Mark McCarty

Panel shoots down non-RCTs, this time for carotid stenting

Oct. 15, 2007

By Mark McCarty

Via tsunami of data, Endeavor DES garners panel thumbs-up

Oct. 12, 2007

By Mark McCarty

Panelist: private equity bubble likely to hit device companies

Oct. 5, 2007

By Mark McCarty

'Scenario planning' critical in world with some other ideas

Oct. 4, 2007

By Mark McCarty

Panel: vascular therapy poses difficulties but then ‘reinvents’

Oct. 4, 2007

By Mark McCarty

‘Scenario planning’ critical in a world with some other ideas

Oct. 3, 2007

By Mark McCarty

FDA panel votes down flexibility in trials for AF catheter ablation

Oct. 1, 2007

By Mark McCarty

800-plus to attend AdvaMed’s inaugural med-tech conference

Sep. 28, 2007

By Mark McCarty

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...